Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × inavolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Neoplasm Metastasis 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 1 PIK3CA-Mutated Cancers 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 HER2-positive Breast Cancer 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 20 blinatumomab 16 fludarabine 13 Cytarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Rituximab 7 Dexamethasone 7 Methotrexate 6 Lenalidomide 6 Daunorubicin 6 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Mercaptopurine 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Cladribine 3 Busulfan 3 Asparaginase 3 tisagenlecleucel 2 thymoglobulin 2 pembrolizumab 2 nilotinib 2 midostaurin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡